https://www.has-sante.fr/jcms/p_3334268/fr/darzalex-daratumumab-myelome-multiple 2022 France evaluation of the transparency committee multiple myeloma daratumumab Myeloma Darzalex Myeloma daratumumab multiple myeloma
--- https://www.has-sante.fr/jcms/p_3320599/fr/darzalex-daratumumab-amylose-systemique-a-chaines-legeres 2022 France evaluation of the transparency committee Darzalex amyloid deposition, nos chain daratumumab daratumumab amyloidosis, nos amylose
--- https://has-sante.fr/jcms/p_3292242/fr/decision-n-2021-0262/dc/sem-du-7-octobre-2021-du-college-de-la-haute-autorite-de-sante-constatant-l-impact-significatif-du-produit-darzalex-daratumumab-1800-mg-sur-les-depenses-de-l-assurance-maladie 2021 France public health guidelines Darzalex Insurance health health expenditures 7-methylbenzanthracene daratumumab daratumumab disease, nos Diseases expenditures schools insurance, health Disease
--- https://has-sante.fr/jcms/p_3183488/fr/darzalex-daratumumab 2020 France evaluation of the transparency committee indicators indicators and reagents daratumumab daratumumab Darzalex traction indication of
--- https://has-sante.fr/jcms/p_3183497/fr/darzalex-daratumumab 2020 France evaluation of the transparency committee daratumumab Darzalex daratumumab